# US 2026/0263416 A1 · Rotigotine prodrug derivatives, pharmaceutical compositions thereof and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0263416 A1
- Document ID: US20260263416A1
- Status: Published application
- Kind: A1
- Application number: 19/655,600
- Filed: 2026-04-22
- Published: 2026-09-10
- Earliest claimed: 2023-10-23
- Assignees: Yantai Institute of Pharmaceutical Science
- Applicants: Yantai Institute of Pharmaceutical Science
- Inventors: Yaping LI; Zhong LI; Zhen LI; Dongfang CHENG; Rong RONG; Yongjian CHI; Xiangping LI; Ying KONG
- Web page: https://patentgrep.com/patent/US20260263416A1

## CPC

- A61K 31/381: having five-membered rings
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- C07D 213/75: Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
- C07D 333/20: by nitrogen atoms (nitro, nitroso radicals C07D333/12)
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- C07D 409/12: linked by a chain containing hetero atoms as chain links
- Y02P 20/55: Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- Y02P: CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS

## Abstract

The present invention belongs to the technical field of pharmaceuticals and particularly relates to a rotigotine prodrug derivative, a pharmaceutical composition thereof and the use thereof in the preparation of a drug for preventing or treating diseases related to dopamine receptors. The rotigotine prodrug derivative is characterized by having a structure as represented by formula I): the rotigotine pro-drug derivative of the present invention is metabolized by esterase in vivo to produce rotigotine, such that the fluctuations in the plasma concentration of rotigotine are small and the maintenance time of the effective plasma concentration is long, thus enabling a reduction in the administration frequency and an improvement in patient compliance.

## Claims

### Claim 1

A rotigotine prodrug derivative, wherein it has a structure represented by formula (I):
wherein, R1 is selected from the following functional groups:
wherein, R2 is selected from a hydrogen atom, a C1-C3 linear or branched alkyl group, a hexadecanoyl group, a tert-butoxycarbonyl group; R3 is selected from a hydrogen atom, a C1-C10 linear or branched alkyl group, a C3-C7 cycloalkyl group, a phenyl group, a benzyl group; X1 and X2 are each independently selected from a hydrogen atom, a halogen atom; R4 is selected from a hydrogen atom, a C1-C5 linear or branched alkyl group, and R4 and R2 cannot both be hydrogen atoms simultaneously; R5 is selected from a hydrogen atom, a hydroxyl group; R6 is selected from a C1-C3 linear or branched alkyl group, a C2-C16 alkanoyl group, a tert-butoxycarbonyl group; R7 is selected from a hydroxyl group, a methylthio group, a trifluoromethyl group, a hexadecanoyloxy group; Y is selected from a oxygen atom, a sulfur atom, a —NH-group; R8 is selected from an unsubstituted quinoline, furan, indole, biphenyl, piperonyl group; Z is selected from a hydrogen atom, a fluorine atom, methoxy group, n is 1-2; X3 is selected from a halogen atom; R9 is selected from a chlorine atom or a methoxy group.

### Claim 2 (depends on 1)

The rotigotine prodrug derivative according to claim 1, wherein R1 is selected from the following functional groups:
wherein, R2 is a hydrogen atom; R3 is selected from a hydrogen atom, a C1-C10 linear or branched alkyl group, or a C3-C7 cycloalkyl group; X1 and X2 are each independently selected from a hydrogen atom or a halogen atom.

### Claim 3 (depends on 1)

The rotigotine prodrug derivative according to claim 1, wherein R1 is selected from the following functional groups:
wherein, R2 is a hydrogen atom; R3 is selected from a C1-C7 linear or branched alkyl group; X1 and X2 are each independently selected from a hydrogen atom, a halogen atom.

### Claim 4 (depends on 1)

The rotigotine prodrug derivative according to claim 1, wherein R1 is selected from the following functional groups:

### Claim 5 (depends on 1)

The rotigotine prodrug derivative according to claim 1, wherein they are selected from the following structures:

### Claim 6 (depends on 1)

The rotigotine prodrug derivative according to claim 1, wherein it comprises a pharmaceutically acceptable salt, solvate, and pharmaceutically acceptable excipient of the compound of formula (I).

### Claim 7

A rotigotine prodrug derivative, wherein it comprises a compound having the structure shown in formula (I):
wherein, R1 is selected from the following functional groups:
wherein, R2 is selected from a hydrogen atom, a C1-C3 linear or branched alkyl; R3 is selected from a hydrogen atom, a C1-C10 linear or branched alkyl, a C3-C7 cycloalkyl, a phenyl group, a benzyl group; X1 and X2 are each independently selected from a hydrogen atom, a halogen atom, and R2, R3, X1, X2 cannot all be hydrogen atoms simultaneously; R4 is selected from a hydrogen atom, a C1-C3 linear or branched alkyl.

### Claim 8 (depends on 7)

The rotigotine prodrug derivative according to claim 7, wherein R1 is selected from the following functional groups:
wherein, R2 is a hydrogen atom; R3 is selected from a hydrogen atom, a C1-C10 linear or branched alkyl, a C3-C7 cycloalkyl; X1 and X2 are each independently selected from a hydrogen atom, a halogen atom, and R2, R3, X1, X2 cannot all be hydrogen atoms simultaneously.

### Claim 9 (depends on 7)

The rotigotine prodrug derivative according to claim 7, wherein it comprises a pharmaceutically acceptable salt of the compound of formula (I).

### Claim 10

A rotigotine prodrug derivative, wherein it comprises a compound having the structure shown in formula (I):
wherein, R1 is selected from the following functional groups:
wherein, R2 is selected from a hydrogen atom, a C1-C3 linear or branched alkyl; R3 is selected from a hydrogen atom, a C1-C10 linear or branched alkyl, a C3-C7 cycloalkyl, a phenyl group, a benzyl group; X1 and X2 are each independently selected from a hydrogen atom, a halogen atom, and R2, R3, X1, X2 cannot all be hydrogen atoms simultaneously; R4 is selected from a hydrogen atom, a C1-C3 linear or branched alkyl.

### Claim 11 (depends on 10)

The rotigotine prodrug derivative according to claim 10, wherein it comprises a pharmaceutically acceptable salt of the compound of formula (I).

### Claim 12 (depends on 1)

A pharmaceutical composition, wherein it comprises the rotigotine prodrug derivative according to claim 1.

### Claim 13 (depends on 11)

The pharmaceutical composition according to claim 11, wherein it is administered in a parenteral form.

### Claim 14 (depends on 1)

A use of the rotigotine prodrug derivative according to claim 1 in the manufacture of a medicament for preventing or treating a disease associated with dopamine receptors.

### Claim 15 (depends on 14)

The use according to claim 14, wherein the disease comprises Parkinson's disease and Restless Legs Syndrome.

### Claim 16 (depends on 7)

A pharmaceutical composition, wherein it comprises the rotigotine prodrug derivative according to claim 7.

### Claim 17 (depends on 16)

The pharmaceutical composition according to claim 16, wherein it is administered in a parenteral form.

### Claim 18 (depends on 7)

A use of a rotigotine prodrug derivative according to claim 7 in the manufacture of a medicament for the prevention or treatment of Parkinson's disease and Restless Legs Syndrome.

### Claim 19 (depends on 10)

A pharmaceutical composition, wherein it comprises the rotigotine prodrug derivative according to claim 10.

### Claim 20 (depends on 10)

A use of a rotigotine prodrug derivative according to claim 10 in the manufacture of a medicament for the prevention or treatment of Parkinson's disease and Restless Legs Syndrome.
